Development of Ternary Amorphous Solid Dispersions Manufactured by Hot-Melt Extrusion and Spray-Drying─Comparison of <i>In Vitro</i> and <i>In Vivo</i> Performance-Reference-Cited by-同舟云学术

Development of Ternary Amorphous Solid Dispersions Manufactured by Hot-Melt Extrusion and Spray-Drying─Comparison of In Vitro and In Vivo Performance

Published:2024-02-12 Issue:3 Volume:21 Page:1309-1320
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Trenkenschuh Eduard¹^ORCID,Blattner Simone M.²,Hirsh David³^ORCID,Hoffmann Ragna¹,Luebbert Christian⁴^ORCID,Schaefer Kerstin¹

Affiliation:

1. Pharmaceutical Development, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany

2. Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany

3. Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States

4. amofor GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00696

Reference47 articles.

1. Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

2. Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development

3. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products

4. Spray drying formulation of amorphous solid dispersions

5. Characterization and performance assessment of solid dispersions prepared by hot melt extrusion and spray drying process

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of rheology in formulation and process design of hot melt extruded amorphous solid dispersions;International Journal of Pharmaceutics;2024-10

2. Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023;International Journal of Pharmaceutics: X;2024-06